These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Rho kinase: an important mediator of atherosclerosis and vascular disease. Zhou Q; Liao JK Curr Pharm Des; 2009; 15(27):3108-15. PubMed ID: 19754385 [TBL] [Abstract][Full Text] [Related]
6. Statins inhibit Rho kinase activity in patients with atherosclerosis. Nohria A; Prsic A; Liu PY; Okamoto R; Creager MA; Selwyn A; Liao JK; Ganz P Atherosclerosis; 2009 Aug; 205(2):517-21. PubMed ID: 19167712 [TBL] [Abstract][Full Text] [Related]
7. Current status of rho-associated kinases (ROCKs) in coronary atherosclerosis and vasospasm. Dong M; Yan BP; Yu CM Cardiovasc Hematol Agents Med Chem; 2009 Oct; 7(4):322-30. PubMed ID: 19607644 [TBL] [Abstract][Full Text] [Related]
8. Rho kinase inhibitors: potential treatments for diabetes and diabetic complications. Zhou H; Li YJ Curr Pharm Des; 2012; 18(20):2964-73. PubMed ID: 22571664 [TBL] [Abstract][Full Text] [Related]
9. Development of Rho-kinase inhibitors for cardiovascular medicine. Shimokawa H; Rashid M Trends Pharmacol Sci; 2007 Jun; 28(6):296-302. PubMed ID: 17482681 [TBL] [Abstract][Full Text] [Related]
10. Does it matter whether or not a lipid-lowering agent inhibits Rho kinase? Liao JK Curr Atheroscler Rep; 2007 Nov; 9(5):384-8. PubMed ID: 18001621 [TBL] [Abstract][Full Text] [Related]
11. Effects of rosuvastatin versus atorvastatin on rho-associated coiled-coil containing protein kinase activity and endothelial function in patients with atherosclerosis. Liu B; Cao HM; Li GY; Liu M; Feng J; Li J; Wang Q J Int Med Res; 2011; 39(6):2314-22. PubMed ID: 22289549 [TBL] [Abstract][Full Text] [Related]
12. ROCKs as therapeutic targets in cardiovascular diseases. Rikitake Y; Liao JK Expert Rev Cardiovasc Ther; 2005 May; 3(3):441-51. PubMed ID: 15889972 [TBL] [Abstract][Full Text] [Related]
13. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Dong M; Yan BP; Liao JK; Lam YY; Yip GW; Yu CM Drug Discov Today; 2010 Aug; 15(15-16):622-9. PubMed ID: 20601092 [TBL] [Abstract][Full Text] [Related]
14. 2015 ATVB Plenary Lecture: translational research on rho-kinase in cardiovascular medicine. Shimokawa H; Satoh K Arterioscler Thromb Vasc Biol; 2015 Aug; 35(8):1756-69. PubMed ID: 26069233 [TBL] [Abstract][Full Text] [Related]
15. Striking crosstalk of ROCK signaling with endothelial function. Noma K; Kihara Y; Higashi Y J Cardiol; 2012 Jul; 60(1):1-6. PubMed ID: 22607993 [TBL] [Abstract][Full Text] [Related]
16. The interplay of signaling pathway in endothelial cells-matrix stiffness dependency with targeted-therapeutic drugs. Vania V; Wang L; Tjakra M; Zhang T; Qiu J; Tan Y; Wang G Biochim Biophys Acta Mol Basis Dis; 2020 May; 1866(5):165645. PubMed ID: 31866415 [TBL] [Abstract][Full Text] [Related]
17. Targeting ROCK signaling in health, malignant and non-malignant diseases. Shahbazi R; Baradaran B; Khordadmehr M; Safaei S; Baghbanzadeh A; Jigari F; Ezzati H Immunol Lett; 2020 Mar; 219():15-26. PubMed ID: 31904392 [TBL] [Abstract][Full Text] [Related]
18. Targeting Rho-associated coiled-coil forming protein kinase (ROCK) in cardiovascular fibrosis and stiffening. Yu B; Sladojevic N; Blair JE; Liao JK Expert Opin Ther Targets; 2020 Jan; 24(1):47-62. PubMed ID: 31906742 [No Abstract] [Full Text] [Related]
19. Rho-kinase as a therapeutic target in vascular diseases: striking nitric oxide signaling. Kolluru GK; Majumder S; Chatterjee S Nitric Oxide; 2014 Dec; 43():45-54. PubMed ID: 25196952 [TBL] [Abstract][Full Text] [Related]